Apimeds Pharmaceuticals US (APUS) Accounts Payables (2023 - 2025)

Apimeds Pharmaceuticals US (APUS) has reported Accounts Payables for 3 consecutive years, with $567633.0 the latest figure, recorded in Q3 2025.

• For the quarter ending Q3 2025, Accounts Payables changed N/A year-over-year to $567633.0; the trailing twelve-month figure through Sep 2025 stood at $567633.0 (changed N/A YoY), and the FY2024 full-year result was $591191.0, up 985.99% from the prior year.
• Accounts Payables rose to $567633.0 in Q3 2025 per APUS's latest filing, from $119138.0 in the prior quarter.
• Across five years, Accounts Payables topped out at $935203.0 in Q1 2025 and bottomed at $54438.0 in Q4 2023.
• Historically, Accounts Payables has averaged $453520.6 across 3 years, with a median of $567633.0 in 2025.
• The widest YoY moves for Accounts Payables: up 985.99% in 2024, down 985.99% in 2024.
• Over 3 years, Accounts Payables stood at $54438.0 in 2023, then surged by 985.99% to $591191.0 in 2024, then declined by 3.98% to $567633.0 in 2025.
• According to Business Quant data, Accounts Payables over the past three periods registered $567633.0, $119138.0, and $935203.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.